TQB2922 / Sino Biopharm - LARVOL DELTA

A first-in-human phase I study of TQB2922, an EGFR/C-MET bispecific antibody, as monotherapy and in combination with bevacizumab and chemotherapy in EGFR-mutant non-small cell lung cancer (ELCC 2026) - P1 | "Funding Chia Tai Tianqing Pharmaceutical Group Co. Ltd."

Bispecific • Combination therapy • First-in-human • Monotherapy • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

TQB2922-I-02: Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Trial completion date: Dec 2028 ➔ Dec 2029 | Trial primary completion date: Dec 2028 ➔ Dec 2029

Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology

Treatment of Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - P1/2 | N=128 | Not yet recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

New P1/2 trial • Head and Neck Cancer • Oncology • Solid Tumor

TQB2922-I-02: Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology

A first-in-human, phase I study of TQB2922: A novel EGFR/c-MET Bispecific Antibody for Advanced EGFR-mutant non-small cell lung cancer (NSCLC) [WITHDRAWN] (ESMO Asia 2025) - No abstract available

First-in-human • Metastases • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

New P1 trial • Oncology

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor • BRAF

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=72 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1/2 trial • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Three new category 1 drugs with new indications from Zhengda Tianqing were approved for clinical trials [Google translation] (Sina Corp) - "On April 8, three innovative Class 1 antibody drugs of Zhengda Tianqing were approved for clinical trials for new indications. These three new drugs are BCMA/CD3 bispecific antibody TQB2934, EGFR/c-Met bispecific antibody TQB2922 and ST2 monoclonal antibody TQC2938. The newly added indications are the treatment of systemic light chain (AL) amyloidosis in adults, the treatment of advanced malignant tumors in combination with other marketed anti-tumor drugs, and the treatment of seasonal allergic rhinitis."

New trial • Allergic Rhinitis • Amyloidosis • Hematological Malignancies

TQB2922-I-01: Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Oncology

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology